Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Oncology > Endocrine Cancer Precision Panel

Endocrine Cancer Precision Panel

The Igenomix Endocrine Cancer Precision Panel has been designed to carry out an accurate and effective diagnosis of hereditary cancer syndromes involving the endocrine and neuroendocrine glands. It provides a comprehensive analysis of the most important genes associated with these types of cancer using next-generation sequencing.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Endocrine neoplasms comprise a variety of benign and malign tumors that arise from the endocrine and neuroendocrine glands. Depending on the tumor type, 10% to 40% of cases are associated with inherited genetic disorders. There are several hereditary syndromes that involve endocrine or neuroendocrine glands, such as multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2A and MEN2B), multiple endocrine neoplasia type 4 (MEN4), SDH-related familial paraganglioma-pheochromocytoma syndromes, Li-Fraumeni syndrome, Neurofibromatosis type 1, familial nonmedullary thyroid cancer syndromes, familial adenomatous polyposis, and von Hippel-Lindau disease.

  • Early detection of endocrine cancer syndromes by molecular analysis methods provides anticipatory guidance for prevention or early detection of manifestations, predict likelihood of tumor progression toward malignancy, uncover targeted treatment options, and offers inherited risk information for family members.

  • As many of the oncologists are used to group and study the different cancer types in systems or specialities, the main objective of this product is to provide them with a more manageable diagnostic tool according to their field of knowledge.

Indication

The Igenomix Endocrine Cancer Precision Panel is indicated in those cases in which the physician requires an accurate diagnosis of individuals with an endocrine tumour and additional features suggestive of a hereditary cancer syndrome. It is designed to ascertain whether a patient with one or more endocrine neoplasms is a spontaneous case or associated with an endocrine cancer syndrome and to act accordingly, providing the patient and even family members with the appropriate management of the condition.

Clinical Utility

The clinical utility of this panel is:  
 
  • Identify pathogenic cancer susceptibility variants
  • Maximize surveillance and preventive strategies for at risk individuals
  • Provide options and strategies for targeted treatment, therapeutic planning, and clinical trials
  • Perform risk assessment and genetic counselling for family members (cascade testing)

Genes & Diseases

Methodology

References

See scientific referrals

Anik, A., & Abaci, A. (2014). Endocrine cancer syndromes: an update. Minerva pediatrica, 66(6), 533–547.

Pilarski, R., & Nagy, R. (2012). Genetic testing by cancer site: endocrine system. Cancer journal (Sudbury, Mass.), 18(4), 364–371. https://doi.org/10.1097/PPO.0b013e3182609458

Laha, D., Nilubol, N., & Boufraqech, M. (2020). New Therapies for Advanced Thyroid Cancer. Frontiers in endocrinology, 11, 82. https://doi.org/10.3389/fendo.2020.00082

Dralle, H., Machens, A., & Lorenz, K. (2008). Hereditäre Schilddrüsenkarzinome [Hereditary thyroid cancer]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 79(11), 1017–1028. https://doi.org/10.1007/s00104-008-1558-y

HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Challenges and opportunities in genetic counseling for hereditary endocrine neoplasia síndromes. Endocrine-Related Cancer (2020) 27, T65–T75; 1530/ERC-19-0454

descargar

Detail description

Download

Request Information


WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
Country/Region

[2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press

Request Information


  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

International
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy